Feeding and Eating Disorders
1 drug in active Feeding and Eating Disorders trials · Updated 20 Nov 2026
Furthest along
1 in Phase 3
Drugs
1
In active trials, any stage
Trials
2 active
2 sub-diseases included
Drugs1
| Drug | How it works | Company | Stage
Sources: FDA: the drug development process, ClinicalTrials.gov glossary | Next date
| Details |
|---|---|---|---|---|---|
Dopamine and norepinephrine reuptake inhibitor |
Phase 3 | Dec 2026Phase 3 trial completes | |||
| Next date | Dec 2026 · Phase 3 trial completes | ||||
| Also tested for | Binge-Eating Disorder | ||||
| Open drug page | |||||
Included2
| Sub-disease | Drugs | Active trialsTrials |
|---|---|---|
| Binge-Eating Disorder | 1 | 2 |
1 more with no active trials: Anorexia Nervosa
About
- Summary
- 1 drug is in active Feeding and Eating Disorders trials. The next Phase 3 result expected is Solriamfetol’s, Dec 2026. Updated 20 Nov 2026.
- Registry term
- Feeding and Eating Disorders
- Counts
- Active trials the registry tags with the term or a term under it, at any stage. A search also reads trial titles and drug names, so its counts differ.
- Sources
- ClinicalTrials.gov updated 20 Nov 2026